Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus

Addition of GLP-1 Therapy to Insulin in C-Peptide-Positive Patients with Type 1 Diabetes

(2018) NITESH D. KUHADIYA et al.   DIABETES

Liraglutide as an Additional Treatment to Insulin in Patients with Type 1 Diabetes Mellitus—A 52-Week Randomized Double-Blinded Placebo-Controlled Clinical Trial

(2018) PARESH DANDONA et al.   DIABETES

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial

(2016) Bo Ahrén et al.   DIABETES CARE

Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks

(2016) Nitesh D. Kuhadiya et al.   DIABETES CARE

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial

(2016) Chantal Mathieu et al.   DIABETES CARE

Obesity and glycemic control in patients with diabetes mellitus: Analysis of physician electronic health records in the US from 2009–2011

(2016) J.P. Bae et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial

(2016) Thomas Fremming Dejgaard et al.   Lancet Diabetes & Endocrinology

Type 1 Diabetes Treatment Beyond Insulin

(2016) Lindsay B. Harrison et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study

(2015) Christian S. Frandsen et al.   DIABETES CARE

Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic Registry

(2015) Kellee M. Miller et al.   DIABETES CARE

Once-Weekly Exenatide as Adjunct Treatment of Type 1 Diabetes Mellitus in Patients Receiving Continuous Subcutaneous Insulin Infusion Therapy

(2014) Andrea N. Traina et al.   Canadian Journal of Diabetes

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: A randomized, open label study

(2013) K.V.S. Hari Kumar et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus

(2013) Nitesh Kuhadiya et al.   Endocrine Practice

Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual  -Cell Function

(2011) U. Kielgast et al.   DIABETES CARE

Liraglutide as additional treatment for type 1 diabetes

(2011) Ajay Varanasi et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Hypoglycemia in Type 1 Diabetes

(2010) R. J. McCrimmon et al.   DIABETES

The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes

(2010) V. S. Raman et al.   DIABETES CARE

Effects of Exenatide Alone and in Combination With Daclizumab on  -Cell Function in Long-Standing Type 1 Diabetes

(2009) K. I. Rother et al.   DIABETES CARE

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE